Pyrazoloadenine

• Description :

  Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity[1][2].

• CAS Number :

  [2380-63-4]

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H319, H335

• Target :

  RET

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pyrazoloadenine.html

• Purity :

  99.98

• Solubility :

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  NC1=C2C(NN=C2)=NC=N1

• Molecular Formula :

  C5H5N5

• Molecular Weight :

  135.13

• Precautions :

  H301, H315, H319, H335

• References & Citations :

  [1]Saha D, et al. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem. 2021 May 18;16 (10) :1605-1608.|[2]SKIPPER HE, et al. Inhibition of experimental neoplasms by 4-aminopyrazolo (3, 4-d) pyrimidine. Proc Soc Exp Biol Med. 1955 Aug;89 (4) :594-6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported